AAV8-3m vector system (Pancreas-validated AAV expression and packaging plasmid system)

GeneMedi (GM) AAV8 variant (Y733F, Y447F, Y275) Vector system is including: 1) AAV8 variant (Y733F, Y447F, Y275) Rep-Cap plasmid (AAV8 variant (Y733F, Y447F, Y275)-RC plasmid) 2) AAV Helper plasmid 3) AAV expression vectors (overexpression or shRNA).

You can produce AAV8 variant (Y733F, Y447F, Y275) particle in 293T cell line in high titer using GeneMedi's AAV8 variant (Y733F, Y447F, Y275) Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

The tissue tropism of AAV8-3m vector has been validated in in Pancreas, Pancreatic Tumors and retina,with potential applications in tissue-specific gene therapy and cancer therapy.

Target products collectionGo to AAV vector system >>



Product Description

Cat.NO Product Name Organization Type Price(In USD)
P-PK12 AAV8 variant(Y733F,Y447F, Y275) Vector System
1. AAV8 variant (Y733F, Y447F, Y275) Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Academic 3024
P-PK12 AAV8 variant(Y733F,Y447F, Y275) Vector System
1. AAV8 variant (Y733F, Y447F, Y275) Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Industry R&D
(excluding
CRO&CDMO&CXO)
P-PK12 AAV8 variant(Y733F,Y447F, Y275) Vector System
1. AAV8 variant (Y733F, Y447F, Y275) Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
 CRO&CDMO&
CXO&CMC&
Manufacturing company
P-PK12-Kan AAV8 variant(Y733F,Y447F, Y275) Vector System(Kan resistance)
1. AAV8 variant (Y733F, Y447F, Y275) Rep-Cap Plasmid(Kan resistance), 10mg
2. AAV Helper Plasmid(Kan resistance), 10mg
3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), 10mg
 All
Currently, GeneMedi only offers amplification services for the Kan-resistant AAV Vector System and do not provide seed stocks.
P-RC12 AAV8 variant(Y733F,Y447F, Y275) Rep-Cap Plasmid
Academic 1719
P-RC12 AAV8 variant(Y733F,Y447F, Y275) Rep-Cap Plasmid
Industry R&D
(excluding
CRO&CDMO&CXO)
P-RC12 AAV8 variant(Y733F,Y447F, Y275) Rep-Cap Plasmid
CRO&CDMO&
CXO&CMC&
Manufacturing company
P-RC12-Kan AAV8 variant(Y733F,Y447F, Y275) Rep-Cap Plasmid(Kan resistance)
All
Currently, GeneMedi only offers amplification services for the Kan-resistant AAV Rep-Cap Plasmids and do not provide seed stocks.
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.
Terms of sale:
For Seed (5ug):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party.

For plasmid production&lification (≥10mg):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party.

Citation

Title Publication Date
A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR Molecular Cancer 2023/1/23
Lipid-accumulated reactive astrocytes promote disease progression in epilepsy Nature Neuroscience 2023/3/20
Apoptosis-resistant megakaryocytes produce large and hyperreactive platelets in response to radiation injury Military Medical Research 2023/12/19
Lysosomal-associated protein transmembrane 5 ameliorates non-alcoholic steatohepatitis by promoting the degradation of CDC42 in mice Nature Communications 2023/5/8
Pulmonary Surfactant Homeostasis Dysfunction Mediates Multiwalled Carbon Nanotubes Induced Lung Fibrosis via Elevating Surface Tension ACS nano 2023/12/15
Photoreceptor protection by mesenchymal stem cell transplantation identifies exosomal MiR-21 as a therapeutic for retinal degeneration Cell Death & Differentiation 2020/10/6
Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma Nat Commun 2019/4/11
SUMO1 regulates post-infarct cardiac repair based on cellular heterogeneity Journal of Pharmaceutical Analysis 2022/12/5
FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis Bone Research 2022/7/22
LncIRS1 controls muscle atrophy via sponging miR-15 family to activate IGF1-PI3K/AKT pathway J Cachexia Sarcopenia Muscle 2019/1/30


Validation data

No data found


Associated products and services


Products & Service Products & Service Information
AAV Packaging service Detail
Promise-ORF™ viral CDNA library Detail
Plasmid DNA Rapid Preparation Service Detail